Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRAM INN is a dietary supplement developed and marketed by the Serbian company INNventa Pharm, specifically formulated for the management and prevention of urinary tract infections (UTIs). The product contains a synergistic combination of D-mannose and cranberry (Vaccinium macrocarpon) fruit extract, often supplemented with Vitamin C (ascorbic acid). Its primary mechanism of action involves the competitive inhibition of bacterial adhesion to the urothelium. D-mannose binds to the FimH adhesins of Type 1 fimbriae on uropathogenic *Escherichia coli* (UPEC), while cranberry proanthocyanidins (PACs) target P-fimbriae. By preventing these bacteria from anchoring to the bladder wall, the supplement facilitates their clearance from the urinary tract during urination. GRAM INN is available in multiple formulations, including standard capsules, a high-dose 'Forte' sachet version, and suppositories for vaginal or rectal use to prevent localized bacterial colonization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GRAM INN.